Diabetes Drug Wins in HFrEF; Swift Shift to TAVR; Neurologists to Tackle HTN? - MedPage Today

Diabetes Drug Wins in HFrEF; Swift Shift to TAVR; Neurologists to Tackle HTN?  MedPage Today

The SGLT2 diabetes drug dapagliflozin (Farxiga) significantly reduced cardiovascular death and worsening of heart failure with reduced ejection fraction in ...



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more